Bausch + Lomb (BLCO) vs. Its Competitors Head to Head Survey

Bausch + Lomb (NYSE:BLCO) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare Bausch + Lomb to related companies based on the strength of its institutional ownership, profitability, risk, valuation, analyst recommendations, earnings and dividends.

Analyst Ratings

This is a summary of current recommendations for Bausch + Lomb and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1	7	6	1	2.47
Bausch + Lomb Competitors	4240	10439	18139	818	2.46

Bausch + Lomb presently has a consensus target price of $19.46, indicating a potential downside of 3.98%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 24.64%. Given Bausch + Lomb’s peers higher possible upside, analysts plainly believe Bausch + Lomb has less favorable growth aspects than its peers.

Risk and Volatility

Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Bausch + Lomb’s peers have a beta of 2.52, suggesting that their average stock price is 152% more volatile than the S&P 500.

Profitability

This table compares Bausch + Lomb and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Bausch + Lomb Competitors	-278.47%	-150.38%	-22.01%

Insider and Institutional Ownership

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 1.5% of Bausch + Lomb shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Bausch + Lomb and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Bausch + Lomb	$5.32 billion	-$360.00 million	-42.23
Bausch + Lomb Competitors	$1.88 billion	$137.23 million	11.24

Bausch + Lomb has higher revenue, but lower earnings than its peers. Bausch + Lomb is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Bausch + Lomb peers beat Bausch + Lomb on 7 of the 13 factors compared.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.